Onkológia 6/2019
Guidelines for the substitution of an erythrocyte-containing transfusion drug in an oncologic patient
Administration of red blood cell transfusion is a part of the therapy of oncologic patients. Up to 90% of cancer patients experience some degree of anemia during chemotherapy and about one third od cancer patients with solid tumors and hematologic malignancies need substitution with cell transfusion. Physicians often use hemoglobin level to decide when to tranfuse, not the symptoms of the patients. The literature about the assessment of the administration of red blood cell transfusion to oncologic patients receiving chemotherapy is lacking. European Society of Medical Oncology (ESMO) issued in 2018 guidelines on the management of anemia in oncologic patients, in which they follow the recommendation of American Association of Blood Banks (AABB) from 2016. Besides the above recommendations, i tis necesary to emphasize specific situations in substituion red cell therapy in hematooncologic patient and patients after allogeneic and autologous hematopoietic stem cell transplantation.
Keywords: red blood cell transfusion, hemoglobin, guidelines, oncologic patient, transplantation
